Ana Maria Roselino

Dr. Ana Maria Roselino


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAna P. Campanelli
Ana P. Campanelli
ARAna Maria Roselino
Ana Maria Roselino
KCKaren A. Cavassani
Karen A. Cavassani
MPMarcelo S. F. Pereira
Marcelo S. F. Pereira
RMRenato A Mortara
Renato A Mortara
JSJoão Santana da Silva
João Santana da Silva
Endogenous regulatory T (Treg) cells are involved in the control of infections, including Leishmania infection in mice. Leishmania viannia braziliens

1 August 2016 in Journal of Autoimmunity
Verified
Journal Article
Closed access
MBMaria José Franco Brochado
Maria José Franco Brochado
DNDaniela Francisca Nascimento
Daniela Francisca Nascimento
WCWagner Campos
Wagner Campos
NDNeifi Hassan Saloum Deghaide
Neifi Hassan Saloum Deghaide
EDEduardo A. Donadi
Eduardo A. Donadi
ARAna Maria Roselino
Ana Maria Roselino

1 April 2002 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
AMA.C.R. Medeiros
A.C.R. Medeiros
SRS.S. Rodrigues
S.S. Rodrigues
ARAna Maria Roselino
Ana Maria Roselino
More precise and rapid diagnostic methods for American cutaneous leishmaniasis (ACL) are necessary because of the growing number of cases observed in Brazil, including the northeastern region of the State of São Paulo. We applied PCR to 54 skin or mucosal biopsies from patients with a clinical and/or laboratory diagnosis of ACL using primers 13A and 13B, with positive results being obtained for 82% of the samples. When the PCR results were compared to those of histopathological leishmania detection, PCR showed superior results with 81.5% sensitivity and 95% CI of 68.0-95.1%. The Montenegro skin test (MST) was positive in 88.7% of patients. Since MST cannot be used as a diagnostic tool in endemic areas, the present results strongly suggest the use of PCR for the etiological confirmation of ACL, with emphasis on the mucosal form.

1 April 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
CSClaudia Giuli Santi
Claudia Giuli Santi
AGAlexandre Carlos Gripp
Alexandre Carlos Gripp
ARAna Maria Roselino
Ana Maria Roselino
DMDanielle Santana Mello
Danielle Santana Mello
JGJuliana Olivieri Gordilho
Juliana Olivieri Gordilho
APAdriana Maria Porro
Adriana Maria Porro
Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone. Mucous membrane pemphigoid and epidermolysis bullosa acquisita can evolve with cicatricial mucosal involvement, leading to respiratory, ocular and/or digestive sequelae with important morbidity. For each of these dermatoses, a literature review covering all therapeutic options was performed. A flowchart, based on the experience and joint discussion among the authors of this consensus, was constructed to provide treatment orientation for these diseases in Brazil. In summary, in the localized, low-risk or non-severe forms, drugs that have immunomodulatory action such as dapsone, doxycycline among others may be a therapeutic option. Topical treatment with corticosteroids or immunomodulators may also be used. Systemic corticosteroid therapy continues to be the treatment of choice for severe forms, especially those involving ocular, laryngeal-pharyngeal and/or esophageal mucosal involvement, as may occur in mucous membrane pemphigoid and epidermolysis bullosa acquisita. Several immunosuppressants are used as adjuvant alternatives. In severe and recalcitrant cases, intravenous immunoglobulin is an alternative that, while expensive, may be used. Immunobiological drugs such as rituximab are promising drugs in this area. Omalizumab has been used in bullous pemphigoid.

28 November 2006 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
AMAna Carolina Fragoso Motta
Ana Carolina Fragoso Motta
MLMárcio Ajudarte Lopes
Márcio Ajudarte Lopes
FIFa Ito
Fa Ito
RCR Carlos‐Bregni
R Carlos‐Bregni
OAOp De Almeida
Op De Almeida
ARAna Maria Roselino
Ana Maria Roselino

1 January 1999 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
MRM.L.O. Rodrigues
M.L.O. Rodrigues
RCR.S. Costa
R.S. Costa
CSC.S. Souza
C.S. Souza
NFN.T. Foss
N.T. Foss
ARAna Maria Roselino
Ana Maria Roselino
Background: Pentavalent antimonials have became of basic importance for the treatment of leishmaniasis. Their most severe side effects have been reported to be increased hepatic enzyme levels and electrocardiographic abnormalities. Nephrotoxicity has been rarely related. Observations: We report a case of generalized cutaneous leishmaniasis involving a 50-year old male patient who was submitted to treatment with meglumine antimoniate (Glucantime). He developed acute renal failure (ARF) due to acute tubular necrosis (ATN), followed by death after receiving a total of 53 ampoules of Glucantime. Conclusions: The treatment with Glucantime was responsible by ARF diagnosed in this patient. The previous urine osmolarity and serum creatinine levels were normal and the autopsy showed ATN. It should be pointed out if ARF may also be explained by massive deposits of immunocomplexes by leishmania antibodies and antigens due to the antigenic break by the antimonial compound, since our patient presented countless lesions covering the entire tegument, similar to the Hexheimer phenomenon, but at the autopsy no glomerular alterations were seen.